Jammu Journal

DelveInsight’s “Membranous Nephropathy Market Insights, Epidemiology and Market Forecast – 2036” report delivers an in-depth understanding of the market dynamics, competitive landscape, key growth drivers, emerging therapies, and future opportunities shaping the global membranous nephropathy market.

Interested to know which membranous nephropathy therapies will capture the highest market share?

Download the report to understand the latest membranous nephropathy market trends and forecasts – https://www.delveinsight.com/report-store/membranous-nephropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from the Membranous Nephropathy Market Report

• Membranous nephropathy accounts for the second most common nephropathy in adults after focal segmental glomerulosclerosis (FSGS).

• Primary Membranous Nephropathy (PMN) accounted for the largest share of market revenue in 2025, primarily driven by its high prevalence as an idiopathic autoimmune kidney disorder.

• It most commonly occurs between 50 to 60 years of age in the US and is more prevalent among males than females.

• According to the National Kidney Foundation, PLA2R-associated membranous nephropathy accounts for 70% of PMN.

• Membranous nephropathy management is challenged by no approved therapies, high treatment costs, and variable patient responses. Long-term immunosuppression carries safety concerns, and the disease’s rarity hinders large trials, slowing progress in developing targeted, effective, and accessible treatment options.

• Emerging drugs such as Obinutuzumab (GAZYVA/GAZYVARO, RG7159, GA101) by Roche, Zanubrutinib (BRUKINSA) by BeOne Medicines, Felzartamab by Biogen, and others have the potential to reshape the treatment landscape.

• Povetacicept could establish a distinct position by simultaneously inhibiting BAFF and APRIL, two key cytokines involved in B-cell maturation and plasma-cell survival.

• Unlike several emerging therapies requiring intravenous or subcutaneous administration, Zanubrutinib (BRUKINSA) offers the advantage of oral administration, providing greater convenience and potentially improving patient adherence.

• Obinutuzumab holds an advantage in clinical maturity and physician familiarity, potentially supporting earlier adoption upon approval as it is already marketed for multiple hematologic malignancies.

• The United States is expected to remain the largest membranous nephropathy market within the 7MM, supported by higher treatment uptake of premium biologics and favorable reimbursement for innovative immunotherapies.

• Leading membranous nephropathy companies include Roche, BeOne Medicines, Biogen, Vertex Pharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Climb Bio, and others.

Gain a competitive edge in the Membranous Nephropathy Market by exploring our in-depth analysis @ Membranous Nephropathy Market Report – https://www.delveinsight.com/report-store/membranous-nephropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr

Membranous Nephropathy Market Overview

The global membranous nephropathy market is evolving as a result of growing awareness of autoimmune kidney disorders, advances in biomarker-guided diagnosis, and an expanding pipeline of targeted therapies. Membranous nephropathy is a rare autoimmune glomerular kidney disease characterized by thickening of the glomerular basement membrane due to immune complex deposition, and is one of the leading causes of nephrotic syndrome in adults.

Rising disease burden of autoimmune and chronic kidney disorders, along with improved disease awareness and diagnosis rates, is supporting the demand for advanced nephrology care and precision treatment approaches. The increasing focus on rare kidney diseases through clinical trials, orphan drug incentives, and strategic research collaborations is fostering therapeutic innovation and advancing the pipeline of novel targeted treatments for membranous nephropathy.

Factors Driving the Growth of the Membranous Nephropathy MarketIncreasing Understanding of Autoimmune Disease Mechanisms

Advances in understanding the autoimmune basis of membranous nephropathy, particularly the role of anti-PLA2R and anti-THSD7A antibodies, are supporting the development of targeted therapies and improving disease diagnosis and monitoring.

Rising Clinical Trial and Research Activity

The membranous nephropathy pipeline is expanding with increasing clinical investigation of anti-CD20 B-cell–depleting therapies, Bruton’s tyrosine kinase (BTK) inhibitors, anti-CD38 plasma cell–targeting therapies, dual APRIL/BAFF inhibitors, complement pathway inhibitors, and CD19-directed B-cell therapies, reflecting growing pharmaceutical interest in rare autoimmune kidney diseases.

Rising Chronic Kidney Disease (CKD) Burden

The increasing prevalence of CKD and growing recognition of autoimmune glomerular disorders are contributing to a larger patient pool requiring effective disease-modifying therapies, supporting demand for innovative treatment options in membranous nephropathy.

Membranous Nephropathy Market Segment Analysis

Primary Membranous Nephropathy (PMN) accounted for the largest share of market revenue in 2025, primarily driven by its high prevalence as an idiopathic autoimmune kidney disorder. In 2025, IMN accounted for approximately 85% of total membranous nephropathy cases in the US, while secondary membranous nephropathy contributed to the remaining approximately 15%, highlighting the dominance of autoimmune origin in disease prevalence.

Among the 7MM, PLA2R antigen accounted for the maximum number of cases of IMN. Across EU4 and the UK, nearly 20,000 IMN patients tested positive for the PLA2R antigen, while around 1,000 were associated with THSD7A, emphasizing the diagnostic importance of these target antigens in IMN.

Membranous Nephropathy Market Regional AnalysisNorth America is Expected to Dominate the Overall Membranous Nephropathy Market

The United States is expected to remain the largest membranous nephropathy market within the 7MM, supported by higher treatment uptake of premium biologics, earlier adoption of novel targeted therapies, greater healthcare spending, and favorable reimbursement for innovative immunotherapies.

Germany, France, Italy, Spain, and the UK represent key European markets within the 7MM framework, with growing adoption of targeted immunotherapies and increasing clinical trial activity driving regional market expansion. Data from Japan indicates that the prevalence of IMN is expected to remain relatively consistent throughout the forecast period from 2026 to 2036, reflecting a stable epidemiological trend across the population.

Advances in biomarker-guided diagnosis, increasing understanding of membranous nephropathy immunopathology, and the development of novel targeted agents are expected to expand treatment options and drive market growth across the 7MM from 2022 to 2036, yielding significant commercial opportunities for existing products and pipeline candidates.

Membranous Nephropathy Key Companies

Membranous Nephropathy Companies include:

• Roche

• BeOne Medicines

• Biogen

• Vertex Pharmaceuticals

• AstraZeneca

• Alexion Pharmaceuticals

• Climb Bio

• And Others

Download the report to understand which factors are driving Membranous Nephropathy Market Trends – https://www.delveinsight.com/sample-request/membranous-nephropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr

Latest Highlights from the Membranous Nephropathy Market

• In April 2026, Climb Bio announced that the US FDA had granted Fast Track Designation (FTD) to budoprutug for the treatment of PMN.

• In February 2026, Roche announced that the Phase III MAJESTY study in adults with primary membranous nephropathy met its primary endpoint, showing statistically significant and clinically meaningful results with obinutuzumab.

• Roche in its Q1 2026 presentation anticipates BLA submission for obinutuzumab in membranous nephropathy in 2026.

• Biogen in its Q1 2026 business update anticipates felzartamab approval in 2028–2030 in primary membranous nephropathy.

• In November 2025, povetacicept was granted Fast Track Designation by the US FDA in PMN.

• In June 2025, Biogen announced the initiation of dosing in the global clinical study, PROMINENT – a Phase III study evaluating the efficacy and safety of felzartamab compared to tacrolimus in adults with PMN, with Phase III data expected to read out in 2029.

• Strategic collaborations between pharmaceutical organizations, clinical research centers, and nephrology institutions continue to accelerate commercialization and adoption of novel membranous nephropathy therapies.

Discover key developments and opportunities in the Membranous Nephropathy Market @ Membranous Nephropathy Market Size – https://www.delveinsight.com/sample-request/membranous-nephropathy-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=akpr

Membranous Nephropathy Market Outlook

The treatment landscape for membranous nephropathy has traditionally relied on supportive care and broad immunosuppressive therapies, including corticosteroids, calcineurin inhibitors, cyclophosphamide, and rituximab, aimed at reducing proteinuria and slowing disease progression. Currently, there are no approved therapies specifically indicated for membranous nephropathy, creating a significant unmet clinical need.

The emerging pipeline is increasingly focused on targeted B-cell and plasma cell-directed therapies designed to reduce pathogenic autoantibody production involved in disease pathogenesis. Obinutuzumab is being investigated for its enhanced B-cell depletion capabilities compared with earlier CD20-targeted therapies. Zanubrutinib, an oral BTK inhibitor, is under evaluation for its potential to suppress autoreactive B-cell signaling and antibody-mediated kidney injury. Felzartamab, an anti-CD38 monoclonal antibody, is being developed to target plasma cells responsible for producing pathogenic autoantibodies such as anti-PLA2R antibodies associated with membranous nephropathy.

As targeted immunologic therapies continue to advance through clinical development, the membranous nephropathy market across the 7MM is expected to witness meaningful growth through 2036, driven by first approvals, expanding treatment access, and continued innovation in precision nephrology.

Scope of the Membranous Nephropathy Market Report

Study Period: 2022–2036

Forecast Period: 2026–2036

Base Year: 2026

Major Membranous Nephropathy Companies: Roche, BeOne Medicines, Biogen, Vertex Pharmaceuticals, AstraZeneca, Alexion Pharmaceuticals, Climb Bio, and others.

Market Segments Covered: Region/Geographies, Drugs/Therapies

Geographies Covered: United States; EU4 (Germany, France, Italy, Spain); United Kingdom; Japan

Key Membranous Nephropathy Therapies: Obinutuzumab (GAZYVA/GAZYVARO, RG7159, GA101), Zanubrutinib (BRUKINSA), Felzartamab, Povetacicept, ALXN1920, Budoprutug, and others.

Competitive Intelligence Analysis: Addressable patient population, market drivers and barriers, cost assumptions and pricing analogues, KOL views, SWOT analysis, reimbursement, conjoint analysis, and unmet needs.

Key Focus Areas: Anti-CD20 B-cell–depleting therapies, BTK inhibitors, anti-CD38 plasma cell–targeting therapies, dual APRIL/BAFF inhibitors, complement pathway inhibitors, and CD19-directed B-cell therapies.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Membranous Nephropathy

4. Key Events

5. Epidemiology and Market Methodology of Membranous Nephropathy

6. Membranous Nephropathy Market Overview at a Glance

7. Disease Background And Overview of Membranous Nephropathy

8. Epidemiology and Patient Population of Membranous Nephropathy

9. Patient Journey of Membranous Nephropathy

10. Emerging Therapies of Membranous Nephropathy

11. Membranous Nephropathy: Seven Major Market Analysis

12. Unmet Needs of Membranous Nephropathy

13. SWOT Analysis of Membranous Nephropathy

14. KOL Views of Membranous Nephropathy

15. Market Access and Reimbursement of Membranous Nephropathy

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

How DelveInsight’s Membranous Nephropathy Market Report Helps CXOs and Business Leaders

• Evaluate the current and future market opportunity across key regions, including the United States, EU4, and Japan, through detailed market forecasts, epidemiology assessments, and growth trend analysis.

• Benchmark leading membranous nephropathy therapies and diagnostic approaches through comprehensive competitive intelligence, company profiling, pipeline evaluation, and clinical development tracking.

• Identify potential licensing, acquisition, co-development, and strategic partnership opportunities by monitoring emerging market participants, novel targeted mechanisms, and recent industry collaborations and investments.

• Assess the impact of upcoming regulatory approvals, technological advancements, reimbursement developments, and product launches on market share, pricing strategies, therapy uptake, and commercial success.

• Support strategic decision-making with insights into key opinion leader (KOL) perspectives, unmet clinical needs, treatment algorithm evolution, patient stratification approaches, and evolving market dynamics within the membranous nephropathy landscape.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/membranous-nephropathy-market